The number of shares and votes in Nanologica AB (publ) has changed during the month of October as a result of the completion of the previously communicated preferential rights issue.
As previously communicated, Nanologica’s board of directors on August 23, 2022, decided on a new share issue of approximately MSEK 94 with preferential rights for existing shareholders, in order to finance intensified investments in preparative chromatography. On October 10, Nanologica announced that the rights issue had been subscribed to 85 percent and that Nanologica through the rights issue had received approximately MSEK 79.8, before transaction costs.
The rights issue has resulted in an increase in the number of shares in Nanologica of 7 980 316 shares during the month of October from 28,165,826 to 36,146,142 shares and an increase in the share capital of approx. SEK 3,272,151 from approx. SEK 11,548,771 SEK to approx. SEK 14,820,923.
As of October 31, 2022, the total number of shares and votes in Nanologica AB amounted to 36 146 142. The new shares are currently under registration at the Swedish Companies Registration Office.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: firstname.lastname@example.org
This information is information that Nanologica AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person above, on October 31, 2022, at 14.00 CET.
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit www.nanologica.com.